The Act on the Reform of the Market for Medicinal Products (“AMNOG”) introduced an early benefit assessment (EBA) of pharmaceuticals in Germany in 2011. According to this law, all pharmaceuticals with a new active agent made available on the market for the first time have to go through a benefit assessment process. A benefit assessment dossier has to be submitted at the time of the market entry...

BACKGROUND AND OBJECTIVE The efficiency and function of the pharmaceutical sector, as a vital portion of the health system, have a significant effect on intermediate and final indices of health. In this research, the structure of the pharmaceutical market in Iran was examined through the calculation of concentration indices in 2011. METHODS In this cross-sectional study, the needed data was g...

The aim of this study was to explore the reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland. The study took the form of semi-structured interviews. Forty-one pharmaceutical companies and pharmaceutical wholesalers were invited to participate in the study. The pharmaceutical companies were the member organizations of Pharm...

  The purpose of this paper is to make explicit how companies in pharmaceutical sector can ensure their position in different markets by relying on a sustainable competitive advantages resulted from using a good defined marketing model. Various factors are highlighted including high research and development roles and costs, hard government regulation in frame of GMP standard, market analysis to...

Most of today's major pharmaceutical companies were founded in the late 19th and early 20th centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin, became mass-manufactured and distributed. Global pharmaceutical market is highly dynamic and is characterized by greater levels of R&D expenditure and extensive regulation of its products. Global pharmaceutical sales are e...

the supply chain represents the critical link between the development of new product and the market in pharmaceutical industry. over the years, improvements made in supply chain operations have focused largely on ways to reduce cost and gain efficiencies in scale. in addition, powerful regulatory and market forces have provided new incentives for pharmaceutical firms to basically rethink the wa...